Shares in SkyePharma (LSE: SKP) and Spire Healthcare (LSE: SPI) are down by 5% and 4% today despite releasing results that were in line with expectations. And, even though both companies have bottom lines that are not particularly impressive, they continue to have upbeat forecasts for the next couple of years. Is this enough, though, to make them more attractive buys than fellow healthcare companies, Shire (LSE: SHP) (NASDAQ: SHPG.US) and BTG (LSE: BTG)?
In the case of SkyePharma, it remains confident regarding its medium term outlook, despite losses widening in 2014 versus 2013. In fact, the drug development company is anticipating a step change in revenue growth during the course of the year, as a number of products launched in recent years are expected to deliver significant top line improvements for the company. Furthermore, 2014s revenue figure was hit hard by an exceptional cost of 26.6m resulting from the repayment of bonds and restructuring at a manufacturing site, thereby making its results appear more disappointing than they perhaps were.
Meanwhile, Spire Healthcare was hit by reductions in the NHS tariff applicable during the course of 2014, which meant that its reported net profit fell from 102m in 2013 to just 6m in 2014. However, its future could be much more upbeat, with it receiving planning consent to open new hospitals in Manchester and Nottingham, as well as a radiotherapy centre in Essex. And, with Spire Healthcare being well capitalised, it seems poised to capture an increasing share of the UKs growing independent healthcare market.
As mentioned, both SkyePharma and Spire Healthcare are set to post improved figures over the next couple of years. However, much of this appears to already be priced in, with Spire Healthcare trading on a price to earnings growth (PEG) ratio of 4.6, and SkyePharmas PEG ratio also being high at 3.1. As such, their share prices may come under further pressure even if they are able to deliver on their upbeat forecasts.
This situation contrasts markedly with that of Shire and BTG. For example, Shire has a PEG ratio of 1.2, while BTGs is just 0.5 both of which indicate good value and that the two companies share prices could move much higher. And, with both stocks being highly profitable at the present time and having relatively strong track records of earnings growth, they appear to be much more appealing investments than SkyePharma and Spire.
Certainly, all four stocks are likely to remain volatile compared to the wider index but, even with this volatility being taken into account, BTG and Shire seem to be worth buying right now.
Of course, they aren’t the only companies that could boost your portfolio returns. With that in mind, the analysts at The Motley Fool have written a free and without obligation guide called 5 Shares You Can Retire On.
The 5 companies in question offer stunning dividend yields, have fantastic long-term potential, and trade at very appealing valuations. As such, they could deliver excellent returns and provide your portfolio with a major boost in 2015 and beyond.
Click here to find out all about them – it’s completely free and without obligation to do so.
Do NOT buy these 3 stocks
Theres lots of opportunity out there in todays market but theres also PLENTY of danger.
In anticipation of Champion Shares PROs brief opening to new members next week, the analyst team behind the Motley Fools most exclusive service has agreed to share 3 stocks they believe YOU would do best to avoid.
PRO research is rarely made available to the general public. To find out the names of these “don’t buy” companies — and to claim your 100% FREE copy of Steer Clear Stocks right away — simply click here.